Bioanalysis
Altasciences’ Commitment to Bioanalytical Excellence
Altasciences’ Commitment to Supporting Pharma and Biotech With Comprehensive Bioanalytical Services
We have been your trusted drug development research partner for over 30 years. We are committed to providing world-class bioanalytical services in support of the preclinical and clinical studies conducted at our cutting-edge facilities, as well as extensive standalone solutions to meet your diverse needs. Our flexible bioanalytical services from discovery to Phase IV empower our clients across every phase of research.
We recently launched the Unveiling the Invisible video campaign to showcase how our bioanalytical solutions provide critical insights that unveil the invisible and drive the creation of your innovative therapies.
RELATED RESOURCES
Our bioanalytical team excels in comprehensive bioanalytical services, including assay and method development, molecular biology, mass spectrometry, ligand binding assays, immunogenicity testing, biomarker analysis, flow cytometry services, and more, to support your journey from discovery through Phase IV.
Below are some resources that highlight our extensive knowledge, and wealth of bioanalytical experience.
- The Altascientist Issue 41: Immunomodulation Assessments for Clinical Trials—Sophisticated Bioanalytical Approaches to Support Complex Modalities
- eBook: Key Considerations for Nonclinical AAV Gene Therapy Development
- eBook: Key Biomarkers of Immunomodulation
- Scientific Research Article: A Novel Hybridization LC-MS/MS Methodology for Quantification of siRNA
- Scientific Research Article: A Validated Capillary Microsampling LC-MS Method for Quantification of ASOs in Mouse Serum
- Scientific Research Article: Microsampling in Pediatric Studies
Altasciences’ Commitment to Supporting Pharma and Biotech With Comprehensive Bioanalytical Services
Greater Montréal, Québec, 11/13, 2024 — Altasciences, a trusted drug development research partner for over 30 years, continues its commitment to providing world-class bioanalytical services. This core business supports both preclinical and clinical studies conducted at Altasciences’ facilities, while also offering an extensive standalone solution to meet the diverse needs of clients. By delivering high-quality, flexible bioanalytical services, Altasciences remains dedicated to advancing drug development and empowering clients across every phase of research.
For three decades now, Altasciences has taken pride in evolving their solutions to meet the needs of pharmaceutical and biotechnology companies of all sizes, including the expansion of their labs in Seattle, WA, Columbia, MO, and Laval, Quebec. Their three state-of-the-art bioanalytical laboratories feature mirrored operations and uniform protocols to maintain consistency and quality across client projects, ensuring reliable, high-quality data regardless of location. This high level of harmonization enables the seamless transfer and sharing of methods across its multiple laboratory sites, allowing the analysis of hundreds of thousands of samples efficiently.
“Our extensive bioanalytical offerings are designed to support both standalone projects and Altasciences' integrated drug development solutions. Whether for preclinical or clinical studies, we provide tailored solutions to meet specific research needs. At Altasciences, we’re committed to facilitating every phase of the scientific journey with precision and care,” said Dr. Lynne Le Sauteur, Vice President of Laboratory Sciences at Altasciences.
Altasciences’ bioanalytical services are built around a comprehensive suite of capabilities tailored for both small and large molecules. Core offerings include drug quantification, metabolite and biomarker analysis, and immunogenicity testing, to support and advance a molecule from discovery to market.
Altasciences’ bioanalytical approach focuses on three core pillars: understanding and anticipating client needs as scientists, creating innovative solutions, and fostering collaboration through transparent communication. This client-centered approach has helped Altasciences build lasting partnerships, assisting clients in meeting complex regulatory standards while maintaining scientific rigor.
To promote Altasciences’ bioanalytical services from discovery to Phase IV, they recently launched their Unveiling the Invisible video campaign to showcase how their bioanalytical solutions provide critical insights that unveil the invisible and drive the creation of innovative therapies.
View the fascinating video series here.
About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 30 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster. To learn more about Altasciences, visit Altasciences.com.
Julie-Ann Cabana
Altasciences
jcabana@altasciences.com
Discover the Dynamic Landscape of GLP-1 Drug Development
In this issue of The Altascientist, we explore the current and future development of GLP-1 receptor agonists (GLP-1 RAs), and the complexities involved in the early phases.
Topics covered include preclinical models, bioanalytical assays, clinical study design, manufacturing, and the expanding applications of GLP-1 drugs in treating various health conditions. Exclusive case studies are also presented.
Questions about your drug development program? Speak with one of our experts.
Related resources that may interest you:
Sensitive ASO Quantitation for Decentralized Trials
In this poster presentation, our scientific team demonstrates the promising future of blood microsampling in decentralized clinical trials to support the development of antisense therapeutic drugs.
Find out how they achieved precision, accuracy, and linearity within acceptance criteria with our sensitive and selective bioanalytical method for determining ASOs. Covering an analytical range of 0.50 – 500 ng/ml, they used dried blood micro-samples collected via the Capitainer® qDBS (10 µL), and analyzed them using hybridization LC-MS/MS.
You may also be interested in the following:
- Microsampling: When Small Steps Lead to Big Outcomes
- Coupling Hybridization LC-MS Workflows With Microsampling
- Sparking the Evolution of Microsampling With the Mitra® VAMS® Device
Development and Validation of LC-MS/MS Assay Methods to Determine Ubrogepant and Atogepant in Human Breast Milk
Implementation of a Semi-Automated Bead Extraction Procedure During Analyte Purification for High Throughput Immunogenicity Assays
Strategy to Increase Throughput and Method Sensitivity for Clinical Immunogenicity Studies
Development of a Hybridization LC-MS Methodology for Quantitation of siRNA in Cynomolgus Monkey
Quantitative Bioanalysis of HT-KIT Vivo-Morpholino Using Hybridization LC-MS/MS